Issued on behalf of BioVaxys Technology Corp.
VANCOUVER – Baystreet.ca News Commentary – Innovation in biotech is rapidly reshaping how we fight cancer, a trend reflected in the upcoming European Society for Medical Oncology (ESMO) conference set for October 17–21 in Berlin, Germany. With the Cleveland Clinic reporting rising cancer rates among young adults, and the American Cancer Society noting an increase in 17 of 34 cancer types among Gen X and Millennial populations, improving outcomes has never been more urgent. Advances in immunotherapy are focusing on personalized vaccine strategies—including neoantigen and mRNA-based approaches—and expanding into earlier-stage treatments such as neoadjuvant therapies, many of which rely on novel delivery systems. Key areas of innovation include neoantigen vaccines, T cell engagers, tumor-infiltrating lymphocytes (TILs), cytokine therapies, and intratumoral platforms. For investors, these developments present compelling opportunities, including recent updates from BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF), Adaptive Biotechnologies Corporation (NASDAQ: ADPT), Pyxis Oncology, Inc. (NASDAQ: PYXS), and GRAIL, Inc. (NASDAQ: GRAL).
According to Vision Research Reports, the Global Oncology Market is expected to reach around US$903.81 billion by 2034, growing a 10.9% CAGR. One aspect of that market involves the Global Market for Cancer Nanotech, which ResearchAndMarkets is predicting to reach US$265.4 billion by 2029, rising at a CAGR of 17.4%.
BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), a clinical-stage biopharmaceutical company, recently announced a new research collaboration with Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) to develop a novel immunotherapeutic approach for treating solid tumors. The partnership combines two complementary technologies: BioVaxys’ DPX™ Immune Educating Platform, designed to train the immune system to recognize and attack disease targets, and Sona’s Targeted Hyperthermia Therapy™ (THT), a photothermal technique that uses their proprietary light-activated Gold Nanorods™ (GNRs) to precisely heat tumors and potentially spark a broader immune response throughout the body.
The research will be conducted at Dalhousie University in Halifax, Nova Scotia, under the leadership of two recognized experts in immuno-oncology: Carman Giacomantonio, MD MSc FRCSC, and Barry Kennedy, PhD, of the Giacomantonio Immuno-Oncology Research Group. Dr. Giacomantonio, who also serves as Sona’s Chief Medical Officer, plays a key role in translating foundational science into applied cancer therapy.
Sona’s GNR-based THT is designed to do more than shrink tumors— it’s intended to convert them into immune-activating hubs, helping the body recognize and attack cancer cells throughout the body, including at distant, untreated sites. These proprietary gold nanorods that are the target of THT are uniquely manufactured without CTAB, a toxic surfactant commonly used in other nanoparticle systems, offering a cleaner and potentially safer profile for clinical development.
In preclinical data presented at the 19th Canadian Melanoma Conference, Sona’s THT combined with a PD-1 inhibitor led to full immune activation in colon cancer models known to resist standard immunotherapy. In contrast, animals given only the PD-1 inhibitor—considered a mainstay in current cancer care—showed no benefit, with tumors mirroring the progression seen in untreated controls.
With a focus on actively educating and directing the immune system, BioVaxys’ DPX™ platform plays a critical role in this collaboration. The patented, non-aqueous formulation is designed to keep antigens localized at the injection site, guiding them to nearby lymph nodes where immune responses are naturally initiated. DPX has shown the ability to generate strong and lasting T cell and B cell responses in both cancer and infectious disease models. By first priming the innate immune system, DPX helps set the stage for a more targeted and sustained adaptive immune response, which is a mechanism supported by both preclinical and clinical research.
A recent study presented by BioVaxys at the Personalized Cancer Vaccine Summit in Boston compared DPX-based formulations to conventional adjuvants such as Montanide, AddaVax, and TiterMax. DPX outperformed all three, showing immune stimulation on par with bone marrow-derived dendritic cells, the current gold standard. Remarkably, DPX triggered immune activation even without carrying a peptide payload, highlighting its potential role as a next-generation immunotherapy backbone.
With its combination of flexibility, tolerability, and commercial scalability, DPX remains central to BioVaxys’ strategy for expanding immune-based treatment across multiple disease areas. The company has signed a binding letter of intent to develop DPX-based vaccines for life-threatening food allergies, while further studies are underway exploring applications across viral, bacterial, and parasitic disease models.
CONTINUED… Read this and more news for BioVaxys Technology Corp. at:
https://biotech-insider.com/the-phoenix-of-biotech-how-a-6m-junior-just-swooped-into-a-potential-billion-dollar-opportunity/
In other industry developments and happenings in the market this week include:
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) recently delivered strong Q1 results with 34% year-over-year growth in its MRD business, led by rising demand for its clonoSEQ® testing platform. Adaptive also recently announced that clonoSEQ, the first and only FDA-cleared test to detect minimal residual disease (MRD) in several blood cancers, received expanded Medicare coverage to include long-term monitoring for mantle cell lymphoma patients in remission.
“Securing coverage for clonoSEQ use in the MCL surveillance setting is a significant win for MCL patients. This coverage expansion enables clinicians to more effectively monitor and manage these patients who are at risk of relapse,” said Ben Eckert, senior vice president, Market Access, Adaptive Biotechnologies. “We believe this determination underscores the clinical utility of clonoSEQ testing and establishes a framework for potential expanded coverage of surveillance testing in other Medicare-covered clonoSEQ indications.”
The platform uses immune sequencing to detect molecular recurrence early, offering physicians a more precise way to track cancer progression and treatment response. As Adaptive expands both reimbursement and clinical utility, its MRD segment is increasingly positioned as a core player in the future of immune-based cancer surveillance.
Pyxis Oncology, Inc. (NASDAQ: PYXS) recently unveiled promising preclinical data on micvotabart pelidotin (MICVO), its first-in-concept antibody-drug conjugate targeting the tumor extracellular matrix. The data showed strong monotherapy and combination results, including durable tumor clearance and immune memory when paired with anti-PD-1 therapy. MICVO’s three-pronged mechanism—direct tumor killing, bystander effect, and immunogenic cell death—could make it a compelling candidate in difficult-to-treat solid tumors.
"Our lead therapeutic candidate micvotabart pelidotin has shown remarkably sustained efficacy in tumor clearance and immune activation across multiple models in preclinical studies, supporting our hypothesis that by targeting EDB+FN and releasing a potent payload in the tumor extracellular matrix, MICVO can potentially destabilize the barrier protecting and feeding the tumor structure while killing other tumor cells,” said Lara S. Sullivan, M.D., President, CEO and Chief Medical Officer of Pyxis Oncology. “These data that deepen our understanding of MICVO’s unique three-pronged mechanism, coupled with clinical findings from our Phase 1 dose escalation study that confirmed strong tumor regression response with MICVO, build on the clear scientific rationale to advance this novel ADC as a monotherapy and in combination with anti-PD-1 therapy in patients with recurrent and metastatic head and neck squamous cell carcinoma and other advanced solid tumors.”
At AACR 2025, GRAIL, Inc. (NASDAQ: GRAL) unveiled new data reinforcing the performance of its Galleri® multi-cancer early detection test, based on real-world results from over 100,000 patients. The test showed strong accuracy in both detecting a cancer signal and identifying the tissue of origin—critical for earlier and more targeted follow-up diagnostics.
"GRAIL has an extensive evidence program that is setting the standard for multi-cancer early detection development that includes a large real-world dataset demonstrating Galleri test performance and implementation," said Josh Ofman, MD, MSHS, President of GRAIL. "The real-world findings being presented at AACR support those observed in our previous clinical studies, highlighting the test's ability to screen for deadly cancers that do not have recommended screening tests. Additional data presented will underscore the potential of GRAIL's ctDNA-based targeted methylation assay for quantifying abnormal promoter methylation, which is a known hallmark of cancer and has shown potential utility as a biomarker in precision oncology."
Additional presentations showcased the potential of GRAIL’s methylation-based ctDNA assay to subtype cancers and detect promoter methylation from a single blood draw. These findings position Galleri and GRAIL’s broader platform as leading tools in the early detection and molecular profiling of hard-to-detect cancers.
Article Source: https://biotech-insider.com/the-phoenix-of-biotech-how-a-6m-junior-just-swooped-into-a-potential-billion-dollar-opportunity/
CONTACT:
Baystreet.ca
cs@baystreet.ca
(250) 661-3391
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed by Baystreet.ca Media Corp (“BAY”) on behalf of USA News Group. BAY does not own any shares of BioVaxys Technology Corp and has not been paid for the dissemination of this article, however the owner(s) of (“BAY”) also own and operate USA News Group, which is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for BioVaxys Technology Corp. advertising and digital media from the company directly. There may be 3rd parties who may have shares of BioVaxys Technology Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of BioVaxys Technology Corp. which were purchased in the open market, and previous private placements with the company directly. MIQ reserves the right to buy and sell, and will buy and sell shares of BioVaxys Technology Corp.at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by BioVaxys Technology Corp.; this is a paid advertisement, we currently own shares of BioVaxys Technology Corp. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Related Stories
